Skip to main content
SpringerLink
Log in

Increased Prevalence of Anti-Third Generation Cyclic Citrullinated Peptide Antibodies in Patients With Rheumatoid Arthritis and CREST Syndrome

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

To investigate the prevalence of anti-third generation cyclic citrullinated peptide antibodies (anti-CCP3) in patients with systemic connective tissue diseases, we assembled a training set consisting of 115 patients with rheumatoid arthritis (RA), 52 with Calcinosis, Raynaud’s phenomenon, oesophageal dysmotility, sclerodactyly, telangiectasia (CREST) syndrome, 21 with scleroderma, 20 with ankylosing spondylitis, 18 with reactive arthritis, 25 with juvenile rheumatoid arthritis (RA), 51 with osteoarthritis, 26 with mixed connective tissue disease, 23 with primary Sjogren’s syndrome, 74 with systemic lupus erythematosus, 49 with Polymyaglia rheumatica, and 39 with polymyositis/dermatomyositis. The commercial enzyme-linked immunosorbent assay (ELISA) was used to detect anti-CCP antibodies, including anti-CCP2 (regular, second generation of CCP antigen) and anti-CCP3 (third generation of CCP antigen) in disease-related specimens and normal controls. These serum samples were also evaluated for anti-centomere antibodies by anti-centromere ELISA kit. The higher frequencies of anti-CCP3 and anti-CCP2 were detected in 75.6 and 70.4% patients with RA, respectively. At the same time, anti-CCP3 (not anti-CCP2) was significantly increased in samples isolated from patients with CREST syndrome. The clinical sensitivity of IgG anti-CCP3 for the patients with CREST syndrome was 29% (15 of 52) and the specificity was 96% (384 of 397), with the exception of the RA group. The anti-centromere antibodies were significantly higher in patients with CREST only. The results of our study suggest that compared to anti-CCP2 assay, the new anti-CCP3 assay can enhance the clinical sensitivity for diagnosis of RA and, as an associate marker combined with anti-centromoere, can distinguish CREST syndrome from other systemic connective tissue diseases, especially RA. The clinical specificity of anti-CCP3 was lower than anti-CCP2 assay in diagnosis of RA because of the crossreaction to the patients with CREST syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Von Muhien, and Tan, E. M. (1995). Antoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum, 24, 323–358.

    Article  Google Scholar 

  2. Senshu, T., Kan, S., Ogawa, H., Manabe, M., and Asaga, H. (1996). Preferential deimination of keratin K1 and filaggrin during the terminal differentiation of human epidermis. Biochem Biophys Res Commun 225, 712–719.

    Article  PubMed  CAS  Google Scholar 

  3. Vossenaar, E. R., Zendman, A. J., van Venrooij, W. J., Pruijn, G. J., (2003), PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioassays 25, 1106–1118.

    Article  CAS  Google Scholar 

  4. ACR Subcommittee on RA Guidelines (2002), Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 46, 328–346.

    Article  CAS  Google Scholar 

  5. Goldbach-Mansky, R., Lee, J., McCoy, A., et al. (2000), Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2, 236–243.

    Article  PubMed  CAS  Google Scholar 

  6. Schellekens, G. A., de Jong, B. A., van den Hoogen, F. H., van de Putte, L. B., and van Venrooij, W. J. (1998), Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101, 273–281.

    Article  PubMed  CAS  Google Scholar 

  7. Schellekens, G. A., Visser, H., de Jong, B. A., et al. (2000), The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinate peptide. Arthritis Rheum 43, 155–163.

    Article  PubMed  CAS  Google Scholar 

  8. Nielen, M. M., van Schaardenburg, D., Reesink, H. W., et al. (2004), Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50, 380–386.

    Article  PubMed  Google Scholar 

  9. Rantapaa-Dahlqvist, S., de Jong, BA, Berglin, E., et al. (2003), Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48, 2741–2749.

    Article  PubMed  CAS  Google Scholar 

  10. Suzuki, K., Sawada, T., Murakami, A., et al. (2003), High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 32, 197–204.

    Article  PubMed  CAS  Google Scholar 

  11. Agrawal, S., Misra, R., and Aggarwal, A. (2007), Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 26, 201–204.

    Article  PubMed  Google Scholar 

  12. Shovman, O., Gilburd, B., Zandman-Goddard, G., et al. (2005), The diagnostic utility of anti-cyclic circullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis. Clin Dev Immunol 12, 197–202.

    Article  PubMed  CAS  Google Scholar 

  13. Vencovsky, J., Machacek, S., Sedova, L., et al. (2003), Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62, 427–430.

    Article  PubMed  CAS  Google Scholar 

  14. Meyer, O., Labarre, C., Dougados, M., et al. (2003), Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62, 120–126.

    Article  PubMed  CAS  Google Scholar 

  15. Forslind, K., Ahlmen, M., Eberhardt, K., et al. (2004), Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63, 1090–1095.

    Article  PubMed  CAS  Google Scholar 

  16. Visser, H., le Cessie, S., Vos, K., Breedveld, F. C., and Hazes, J. M. (2002), How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum, 4, 357–365.

    Article  Google Scholar 

  17. Orbach, H., Gilburd, B., Brickman, C., Gerli, R., and Shoenfeld, Y. (2002), Anti-cyclic peptide antibodies as a diagnostic test for rheumatoid arthritis and predictor of an erosive disease. IMAJ 4, 892–893.

    PubMed  Google Scholar 

  18. Baeten, D., Peene, I., Union, A., et al. (2001), Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum, 44, 2255–2262.

    Article  PubMed  CAS  Google Scholar 

  19. van Boekel, M. A., Vossenaar, E. R., van den Hoogen, F. H., van Venrooij, W. J. (2002), Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 4, 87–93.

    Article  PubMed  Google Scholar 

  20. Vossenaar, E. R. and van Venrooij, W. J. (2004) Anti-CCP antibodies, a specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 4, 239–262.

    Article  CAS  Google Scholar 

  21. Vallbracht, I., Rieber, J., Oppermann, M., Forger, F., Siebert, U., and Helmke, K. (2004), Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63, 1079–1084.

    Article  PubMed  CAS  Google Scholar 

  22. Bas, S., Genevay, S., Meyer, O., and Gabay, C. (2003), Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 42, 677–680.

    Article  CAS  Google Scholar 

  23. van Jaarsveld, C-.H., ter Borg, E. J., Jacobs, J. W., et al. (1999), The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol. 17, 689–697.

    PubMed  Google Scholar 

  24. Saraux, A., Berthelot, J. M., Devauchelle, V., et al. (2003), Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatoln 30, 2535–2539.

    CAS  Google Scholar 

  25. Vittecoq, O., Incaurgarat, B., Jouen-Beades, F., et al. (2004), Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 135, 173–180.

    Article  PubMed  CAS  Google Scholar 

  26. Arnett, F. C., Edworthy, S. M., Bloch, D. A., et al. (1988), The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315–324.

    Article  PubMed  CAS  Google Scholar 

  27. Zeng, X., Ai, M., Tian, X., et al. (2003), Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis. J Rheumatol 30, 1451–1455.

    PubMed  CAS  Google Scholar 

  28. Mediwake, R., Isenberg, D. A., Schellekens, G. A., and van Venrooij, W. J. (2001), Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 60, 67–68.

    Article  PubMed  CAS  Google Scholar 

  29. Lopez-Hoyos, M., Ruiz de Algegria, C., Blanco, R., et al. (2004), Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford) 43, 655–657.

    Article  CAS  Google Scholar 

  30. Gottenberg, J. E., Mignot, S., Nicaise-Rolland, P., et al. (2005), Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren’s syndrome. Ann Rheum Dis 64, 114–147.

    Article  PubMed  CAS  Google Scholar 

  31. Kamali, S., Polat, N. G., Kasapoglu, E., et al. (2005), Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjogren’s syndrome, and Wegener’s granulomatosis. Clin Rheumatol 24, 673–676.

    Article  PubMed  Google Scholar 

  32. Alenius, G. M., Berglin, E., Rantapaa Dahlqvist, S., (2006), Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 65, 398–400.

    Article  PubMed  CAS  Google Scholar 

  33. Vossenaar, E. R., Smeets, T. J., Kraan, M. C., Raats, J. M., van Venrooij, W. J., and Tak, P. P. (2004), The presence of citrullinated proteins is not specific for rheumatoid synovial tissue., Arthritis Rheum 50, 3485–3494.

    Article  PubMed  CAS  Google Scholar 

  34. Fritzler, M. J., and Kinsella, T. D. (1980), The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69, 520–526.

    Article  PubMed  CAS  Google Scholar 

  35. Weiner, E. S., Earnshaw, W. C., Senecal, J. L., Bordwell, B., Johnson, P., and Rothfield, N. F. (1988), Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 31, 378–385.

    Article  PubMed  CAS  Google Scholar 

  36. Tan, E. M., Rodnan, G. P., Garcia, J., Moroi, Y., Fritzler, M. J., and Peebles, C. (1980), Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23, 617–625.

    Article  PubMed  CAS  Google Scholar 

  37. Caramaschi, P., Biasi, D., Manzo, T., Carletto, A., Poli, F., and Bambara, L. M. (1995), Anticentromere antibody—clinical associations. A study of 44 patients. Rheumatol of Int 14, 253–255.

    Article  CAS  Google Scholar 

  38. Zuber, M., Gotzen, R., Filler, I. (1994), Clinical correlation of anticentromere antibodies. Clin Rheumatol 13, 427–432.

    Article  PubMed  CAS  Google Scholar 

  39. Miyawaki, S., Asanuma, H., Nishiyama, S., and Yoshinaga, Y. (2005), Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 32, 1488–1494.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pathway diagnostic, Inc., Malibu, CA, USA

    R. Wu

  2. Department of Medicine ’B’, Center for Autoimmune Diseases, Sheba Medical Center, Israel

    O. Shovman, B. Gilburd, G. Zandman-Goodard & Yehuda Shoenfeld

  3. Premiere Oncology, Santa Monica, CA, USA

    Y. Zhang

  4. Sackler Faculty of Medicine, Tel-Aviv University, Israel

    Yehuda Shoenfeld

Authors
  1. R. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Shovman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Gilburd
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Zandman-Goodard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yehuda Shoenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, R., Shovman, O., Zhang, Y. et al. Increased Prevalence of Anti-Third Generation Cyclic Citrullinated Peptide Antibodies in Patients With Rheumatoid Arthritis and CREST Syndrome. Clinic Rev Allerg Immunol 32, 47–55 (2007). https://doi.org/10.1007/BF02686081

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02686081

Index Entries

Search

Navigation